Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis.

Gandhi J, Khera L, Gaur N, Paul C, Kaul R.

Front Microbiol. 2017 Mar 28;8:538. doi: 10.3389/fmicb.2017.00538. eCollection 2017. Review.

2.

Epstein-Barr virus in the pathogenesis of oral cancers.

Guidry JT, Birdwell CE, Scott RS.

Oral Dis. 2017 Feb 11. doi: 10.1111/odi.12656. [Epub ahead of print]

PMID:
28190296
3.

Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.

Ali AS, Al-Shraim M, Al-Hakami AM, Jones IM.

Open Virol J. 2015 Nov 3;9:7-28. doi: 10.2174/1874357901509010007. eCollection 2015.

4.

Serodiagnosis for tumor viruses.

Morrison BJ, Labo N, Miley WJ, Whitby D.

Semin Oncol. 2015 Apr;42(2):191-206. doi: 10.1053/j.seminoncol.2014.12.024. Epub 2014 Dec 31. Review.

5.

Epstein-Barr virus and the origin of Hodgkin lymphoma.

Vockerodt M, Cader FZ, Shannon-Lowe C, Murray P.

Chin J Cancer. 2014 Dec;33(12):591-7. doi: 10.5732/cjc.014.10193. Epub 2014 Nov 21. Review.

6.

Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Coghill AE, Hildesheim A.

Am J Epidemiol. 2014 Oct 1;180(7):687-95. doi: 10.1093/aje/kwu176. Epub 2014 Aug 28. Review.

7.

Combined linkage and association studies show that HLA class II variants control levels of antibodies against Epstein-Barr virus antigens.

Pedergnana V, Syx L, Cobat A, Guergnon J, Brice P, Fermé C, Carde P, Hermine O, Le-Pendeven C, Amiel C, Taoufik Y, Alcaïs A, Theodorou I, Besson C, Abel L.

PLoS One. 2014 Jul 15;9(7):e102501. doi: 10.1371/journal.pone.0102501. eCollection 2014.

8.

Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children's Oncology Group study.

Linabery AM, Erhardt EB, Fonstad RK, Ambinder RF, Bunin GR, Ross JA, Spector LG, Grufferman S.

Int J Cancer. 2014 Sep 15;135(6):1454-69. doi: 10.1002/ijc.28785. Epub 2014 Mar 18.

9.

Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma.

McAllister SC, Shedd D, Mueller NE, Chang ET, Miller G, Bhaduri-McIntosh S.

J Med Virol. 2014 Sep;86(9):1621-8. doi: 10.1002/jmv.23761. Epub 2013 Sep 30.

10.

Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.

Hill ER, Koganti S, Zhi J, Megyola C, Freeman AF, Palendira U, Tangye SG, Farrell PJ, Bhaduri-McIntosh S.

J Virol. 2013 Nov;87(21):11438-46. doi: 10.1128/JVI.01762-13. Epub 2013 Aug 21.

11.

Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.

Levin LI, Chang ET, Ambinder RF, Lennette ET, Rubertone MV, Mann RB, Borowitz M, Weir EG, Abbondanzo SL, Mueller NE.

Blood. 2012 Nov 1;120(18):3750-5. doi: 10.1182/blood-2011-12-390823. Epub 2012 Sep 12.

12.

Cancer incidence and mortality trends in Australian adolescents and young adults, 1982-2007.

Haggar FA, Preen DB, Pereira G, Holman CD, Einarsdottir K.

BMC Cancer. 2012 Apr 20;12:151. doi: 10.1186/1471-2407-12-151.

13.

Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Huang SH, Kozak PJ, Kim J, Habineza-Ndikuyeze G, Meade C, Gaurnier-Hausser A, Patel R, Robertson E, Mason NJ.

Virology. 2012 Jun 5;427(2):107-17. doi: 10.1016/j.virol.2012.02.013. Epub 2012 Mar 8.

14.

11. Cancers attributable to infection in the UK in 2010.

Parkin DM.

Br J Cancer. 2011 Dec 6;105 Suppl 2:S49-56. doi: 10.1038/bjc.2011.484. No abstract available.

15.

Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.

Mueller NE, Lennette ET, Dupnik K, Birmann BM.

Int J Cancer. 2012 Jun 15;130(12):2886-91. doi: 10.1002/ijc.26334. Epub 2011 Aug 30.

16.

Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus.

Ikuta K, Ding M, Zhang F, Sixbey JW, Scott RS.

J Virol. 2011 Aug;85(15):7634-43. doi: 10.1128/JVI.00045-11. Epub 2011 May 18.

17.

Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation.

Clarke CA, Glaser SL, Gomez SL, Wang SS, Keegan TH, Yang J, Chang ET.

Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1064-77. doi: 10.1158/1055-9965.EPI-11-0038. Epub 2011 Apr 14.

18.

Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP, Lou PJ, Cheng YJ, Gravitt P, Diehl SR, Goldstein AM, Chen CJ, Hildesheim A.

Clin Cancer Res. 2011 Apr 1;17(7):1906-14. doi: 10.1158/1078-0432.CCR-10-1681. Epub 2011 Mar 29.

19.

Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Gu AD, Lu LX, Xie YB, Chen LZ, Feng QS, Kang T, Jia WH, Zeng YX.

J Transl Med. 2009 Aug 23;7:73. doi: 10.1186/1479-5876-7-73.

20.

Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo.

Ikuta K, Srinivas SK, Schacker T, Miyagi J, Scott RS, Sixbey JW.

J Virol. 2008 Dec;82(23):11516-25. doi: 10.1128/JVI.01036-08. Epub 2008 Sep 25.

Supplemental Content

Support Center